| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B virus | 54 | 2025 | 157 | 13.280 |
Why?
|
| Virus Replication | 38 | 2021 | 88 | 7.660 |
Why?
|
| RNA Interference | 36 | 2020 | 45 | 6.670 |
Why?
|
| Genetic Therapy | 18 | 2021 | 35 | 5.940 |
Why?
|
| Hepatitis B | 27 | 2025 | 125 | 5.860 |
Why?
|
| RNA, Small Interfering | 23 | 2017 | 49 | 5.170 |
Why?
|
| Hepatitis B, Chronic | 19 | 2025 | 45 | 5.150 |
Why?
|
| MicroRNAs | 20 | 2025 | 34 | 4.840 |
Why?
|
| Genetic Vectors | 32 | 2025 | 55 | 4.680 |
Why?
|
| DNA, Viral | 15 | 2021 | 165 | 3.230 |
Why?
|
| Gene Silencing | 16 | 2021 | 20 | 3.030 |
Why?
|
| Animals | 51 | 2025 | 1081 | 2.960 |
Why?
|
| DNA, Circular | 11 | 2021 | 12 | 2.920 |
Why?
|
| Liver | 20 | 2021 | 74 | 2.870 |
Why?
|
| Adenoviridae | 10 | 2016 | 39 | 2.820 |
Why?
|
| Liver Neoplasms | 19 | 2022 | 59 | 2.350 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2022 | 51 | 2.130 |
Why?
|
| Gene Expression | 17 | 2021 | 43 | 2.100 |
Why?
|
| Humans | 91 | 2025 | 14537 | 1.960 |
Why?
|
| Mice | 29 | 2025 | 135 | 1.770 |
Why?
|
| RNA, Viral | 11 | 2020 | 303 | 1.760 |
Why?
|
| RNA, Messenger | 11 | 2022 | 32 | 1.690 |
Why?
|
| DNA | 10 | 2020 | 73 | 1.650 |
Why?
|
| Trans-Activators | 16 | 2025 | 23 | 1.630 |
Why?
|
| Dependovirus | 5 | 2025 | 9 | 1.360 |
Why?
|
| Helper Viruses | 3 | 2014 | 5 | 1.290 |
Why?
|
| Cell Line | 22 | 2021 | 93 | 1.240 |
Why?
|
| Transfection | 18 | 2021 | 29 | 1.160 |
Why?
|
| Mutation | 6 | 2017 | 306 | 1.150 |
Why?
|
| RNA, Guide | 2 | 2017 | 3 | 1.120 |
Why?
|
| Gene Editing | 4 | 2024 | 5 | 1.060 |
Why?
|
| Antiviral Agents | 8 | 2021 | 111 | 1.060 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 4 | 2021 | 4 | 1.040 |
Why?
|
| Guanidines | 3 | 2015 | 8 | 1.030 |
Why?
|
| Promoter Regions, Genetic | 9 | 2019 | 36 | 0.970 |
Why?
|
| Base Sequence | 21 | 2016 | 149 | 0.960 |
Why?
|
| Plasmids | 10 | 2020 | 23 | 0.930 |
Why?
|
| Mice, Transgenic | 9 | 2025 | 13 | 0.880 |
Why?
|
| Gene Expression Regulation, Viral | 8 | 2025 | 12 | 0.840 |
Why?
|
| Hepacivirus | 4 | 2017 | 37 | 0.820 |
Why?
|
| Hepatitis C, Chronic | 2 | 2017 | 26 | 0.810 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2022 | 20 | 0.780 |
Why?
|
| CRISPR-Cas Systems | 2 | 2024 | 6 | 0.780 |
Why?
|
| Repressor Proteins | 2 | 2019 | 7 | 0.760 |
Why?
|
| HEK293 Cells | 12 | 2021 | 39 | 0.750 |
Why?
|
| RNAi Therapeutics | 2 | 2020 | 2 | 0.750 |
Why?
|
| Hepatocytes | 6 | 2017 | 19 | 0.750 |
Why?
|
| RNA, Catalytic | 4 | 2015 | 5 | 0.740 |
Why?
|
| Hepatitis C | 4 | 2015 | 37 | 0.730 |
Why?
|
| Molecular Sequence Data | 18 | 2014 | 263 | 0.720 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 44 | 0.710 |
Why?
|
| Genes, Viral | 2 | 2020 | 11 | 0.710 |
Why?
|
| Genetic Techniques | 2 | 2019 | 9 | 0.710 |
Why?
|
| Liver Cirrhosis | 4 | 2017 | 28 | 0.710 |
Why?
|
| RNA, Long Noncoding | 2 | 2022 | 3 | 0.690 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2019 | 5 | 0.660 |
Why?
|
| Genes, Reporter | 7 | 2016 | 12 | 0.660 |
Why?
|
| Oligonucleotides | 4 | 2015 | 19 | 0.650 |
Why?
|
| Poly A | 1 | 2019 | 1 | 0.630 |
Why?
|
| Cell Line, Tumor | 10 | 2016 | 71 | 0.600 |
Why?
|
| Vaccination | 1 | 2020 | 365 | 0.600 |
Why?
|
| Polymerase Chain Reaction | 11 | 2020 | 260 | 0.590 |
Why?
|
| DNA Repair | 3 | 2003 | 11 | 0.590 |
Why?
|
| Hep G2 Cells | 6 | 2021 | 14 | 0.590 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 45 | 0.570 |
Why?
|
| Virus Diseases | 3 | 2017 | 55 | 0.550 |
Why?
|
| Deoxyribonuclease I | 1 | 2017 | 1 | 0.550 |
Why?
|
| Viral Regulatory and Accessory Proteins | 15 | 2025 | 27 | 0.540 |
Why?
|
| Biomedical Research | 1 | 2017 | 49 | 0.540 |
Why?
|
| Transcription, Genetic | 6 | 2019 | 14 | 0.540 |
Why?
|
| Immunity, Innate | 1 | 2016 | 10 | 0.540 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 252 | 0.530 |
Why?
|
| Liver Diseases | 3 | 2017 | 18 | 0.520 |
Why?
|
| RNA Polymerase II | 3 | 2014 | 3 | 0.510 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2015 | 1 | 0.480 |
Why?
|
| Hepatitis B Surface Antigens | 7 | 2025 | 48 | 0.470 |
Why?
|
| Hepatitis B Vaccines | 4 | 2022 | 40 | 0.460 |
Why?
|
| Gene Transfer Techniques | 4 | 2014 | 5 | 0.440 |
Why?
|
| HIV Infections | 3 | 2022 | 5097 | 0.440 |
Why?
|
| Deoxyribonucleases | 1 | 2013 | 1 | 0.430 |
Why?
|
| Transduction, Genetic | 2 | 2013 | 3 | 0.420 |
Why?
|
| Cytokines | 4 | 2016 | 107 | 0.410 |
Why?
|
| Polyethylene Glycols | 2 | 2009 | 49 | 0.380 |
Why?
|
| Biological Products | 1 | 2011 | 7 | 0.380 |
Why?
|
| HIV-1 | 6 | 2012 | 1260 | 0.380 |
Why?
|
| Vaccines | 2 | 2023 | 86 | 0.370 |
Why?
|
| RNA, Transfer, Lys | 1 | 2010 | 1 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2000 | 7 | 0.350 |
Why?
|
| RNA, Antisense | 2 | 2007 | 3 | 0.320 |
Why?
|
| Organophosphorus Compounds | 3 | 2015 | 3 | 0.320 |
Why?
|
| Polyamines | 1 | 2008 | 1 | 0.310 |
Why?
|
| Heterocyclic Compounds | 1 | 2008 | 3 | 0.310 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 2 | 2020 | 2 | 0.310 |
Why?
|
| Liposomes | 5 | 2016 | 33 | 0.310 |
Why?
|
| Cholesterol Esters | 1 | 2008 | 2 | 0.310 |
Why?
|
| Open Reading Frames | 2 | 2019 | 16 | 0.310 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2017 | 14 | 0.300 |
Why?
|
| Piperazines | 1 | 2008 | 82 | 0.300 |
Why?
|
| HeLa Cells | 4 | 2020 | 15 | 0.270 |
Why?
|
| Transcriptional Activation | 6 | 2015 | 6 | 0.270 |
Why?
|
| Transgenes | 3 | 2020 | 3 | 0.260 |
Why?
|
| Genes, gag | 1 | 2006 | 6 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 10 | 0.260 |
Why?
|
| Nanoparticles | 3 | 2020 | 104 | 0.260 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2015 | 6 | 0.250 |
Why?
|
| Asialoglycoprotein Receptor | 2 | 2016 | 2 | 0.250 |
Why?
|
| Recombination, Genetic | 2 | 2016 | 27 | 0.250 |
Why?
|
| DNA Replication | 2 | 2016 | 3 | 0.240 |
Why?
|
| Luciferases, Firefly | 2 | 2015 | 2 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2015 | 34 | 0.240 |
Why?
|
| Protein Engineering | 2 | 2015 | 7 | 0.230 |
Why?
|
| Prealbumin | 2 | 2014 | 2 | 0.230 |
Why?
|
| Africa | 3 | 2024 | 376 | 0.230 |
Why?
|
| Transcription Factors, TFII | 1 | 2003 | 1 | 0.220 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 8 | 0.220 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 15 | 0.220 |
Why?
|
| Carrier Proteins | 1 | 2003 | 23 | 0.220 |
Why?
|
| Sulfites | 2 | 2015 | 2 | 0.220 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2015 | 35 | 0.220 |
Why?
|
| Cells, Cultured | 3 | 2013 | 79 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 150 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 17 | 0.210 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 2 | 2021 | 5 | 0.210 |
Why?
|
| Viral Vaccines | 1 | 2022 | 24 | 0.200 |
Why?
|
| Podophyllin | 1 | 2002 | 2 | 0.200 |
Why?
|
| Genes, MDR | 1 | 2002 | 4 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2002 | 8 | 0.200 |
Why?
|
| Estradiol | 1 | 2002 | 18 | 0.200 |
Why?
|
| RNA | 2 | 2015 | 26 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2000 | 3 | 0.200 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 62 | 0.190 |
Why?
|
| Green Fluorescent Proteins | 5 | 2017 | 9 | 0.190 |
Why?
|
| beta-Galactosidase | 3 | 2016 | 3 | 0.190 |
Why?
|
| Blotting, Northern | 7 | 2010 | 11 | 0.190 |
Why?
|
| Cytoplasm | 3 | 2015 | 7 | 0.190 |
Why?
|
| Cytomegalovirus | 2 | 2014 | 24 | 0.190 |
Why?
|
| Endonucleases | 2 | 2021 | 2 | 0.190 |
Why?
|
| Lentivirus | 3 | 2017 | 3 | 0.180 |
Why?
|
| RNA, Small Nuclear | 3 | 2010 | 3 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 2 | 0.180 |
Why?
|
| DNA Methylation | 2 | 2019 | 19 | 0.180 |
Why?
|
| Dengue | 2 | 2011 | 5 | 0.180 |
Why?
|
| Nucleic Acid Conformation | 3 | 2010 | 7 | 0.180 |
Why?
|
| Zinc Finger Nucleases | 1 | 2020 | 1 | 0.170 |
Why?
|
| Ribonucleases | 1 | 2020 | 1 | 0.170 |
Why?
|
| Proto-Oncogenes | 2 | 1991 | 2 | 0.170 |
Why?
|
| DNA Viruses | 2 | 2021 | 3 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 4 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 2 | 2022 | 24 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 131 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 125 | 0.170 |
Why?
|
| Apoptosis | 1 | 2000 | 40 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 112 | 0.170 |
Why?
|
| CpG Islands | 1 | 2019 | 6 | 0.170 |
Why?
|
| Health Care Sector | 1 | 2019 | 8 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 7 | 2003 | 20 | 0.160 |
Why?
|
| Lac Operon | 2 | 2016 | 2 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 20 | 0.160 |
Why?
|
| alpha-Fetoproteins | 2 | 1996 | 2 | 0.160 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 1996 | 2 | 0.160 |
Why?
|
| DNA Polymerase III | 2 | 2010 | 2 | 0.160 |
Why?
|
| Organ Specificity | 3 | 2015 | 10 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 74 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2017 | 33 | 0.150 |
Why?
|
| Hepatic Stellate Cells | 1 | 2017 | 1 | 0.150 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 1 | 0.150 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 2 | 0.150 |
Why?
|
| South Africa | 2 | 2022 | 7596 | 0.150 |
Why?
|
| Base Pair Mismatch | 2 | 2015 | 2 | 0.140 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2012 | 4 | 0.140 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antibodies | 1 | 1997 | 25 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 43 | 0.140 |
Why?
|
| DNA Damage | 1 | 1997 | 12 | 0.140 |
Why?
|
| Cholestasis | 1 | 2017 | 3 | 0.140 |
Why?
|
| DNA Cleavage | 1 | 2017 | 1 | 0.140 |
Why?
|
| Patient Safety | 1 | 2017 | 9 | 0.140 |
Why?
|
| INDEL Mutation | 1 | 2017 | 16 | 0.140 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2016 | 1 | 0.140 |
Why?
|
| Pteridines | 1 | 2016 | 3 | 0.140 |
Why?
|
| Blotting, Western | 6 | 2009 | 14 | 0.130 |
Why?
|
| Cell Survival | 4 | 2009 | 48 | 0.130 |
Why?
|
| 5' Untranslated Regions | 1 | 2016 | 7 | 0.130 |
Why?
|
| Infant | 1 | 2022 | 2244 | 0.130 |
Why?
|
| Galactose | 1 | 2016 | 1 | 0.130 |
Why?
|
| Ligands | 1 | 2016 | 33 | 0.130 |
Why?
|
| Thermus | 1 | 1995 | 1 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 119 | 0.130 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1995 | 5 | 0.130 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1995 | 8 | 0.130 |
Why?
|
| RNA Editing | 1 | 2015 | 3 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2015 | 7 | 0.120 |
Why?
|
| RNA Cleavage | 1 | 2015 | 1 | 0.120 |
Why?
|
| Cell Division | 4 | 2007 | 12 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 181 | 0.120 |
Why?
|
| Genomics | 1 | 2016 | 109 | 0.120 |
Why?
|
| Plants | 1 | 2015 | 1 | 0.120 |
Why?
|
| Recombinant Proteins | 3 | 2003 | 73 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 18 | 0.120 |
Why?
|
| Viral Proteins | 2 | 2007 | 30 | 0.120 |
Why?
|
| Polymers | 1 | 2015 | 133 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2006 | 9 | 0.110 |
Why?
|
| Female | 5 | 2021 | 9103 | 0.110 |
Why?
|
| Gene Order | 1 | 2013 | 1 | 0.110 |
Why?
|
| Cloning, Molecular | 7 | 2015 | 26 | 0.110 |
Why?
|
| Mutagenesis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Genome, Viral | 1 | 2013 | 64 | 0.110 |
Why?
|
| RNA Polymerase III | 2 | 2010 | 5 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 2 | 0.100 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2010 | 2 | 0.100 |
Why?
|
| beta Catenin | 3 | 2009 | 5 | 0.100 |
Why?
|
| Mice, Nude | 6 | 2007 | 12 | 0.100 |
Why?
|
| Cations | 2 | 2009 | 7 | 0.100 |
Why?
|
| Inverted Repeat Sequences | 1 | 2012 | 3 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2012 | 7 | 0.100 |
Why?
|
| Rift Valley fever virus | 1 | 2012 | 3 | 0.100 |
Why?
|
| Succinates | 1 | 2011 | 3 | 0.100 |
Why?
|
| Anti-HIV Agents | 3 | 2010 | 1324 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 151 | 0.090 |
Why?
|
| Genes, myc | 1 | 1991 | 6 | 0.090 |
Why?
|
| DNA, Complementary | 5 | 2004 | 17 | 0.090 |
Why?
|
| Interferons | 2 | 2010 | 9 | 0.090 |
Why?
|
| Viral Tropism | 1 | 2010 | 9 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2010 | 7 | 0.090 |
Why?
|
| RNA Precursors | 1 | 2010 | 2 | 0.090 |
Why?
|
| Dipeptides | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hepatitis B Antigens | 3 | 2006 | 6 | 0.080 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2009 | 4 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2009 | 17 | 0.080 |
Why?
|
| DNA Primers | 2 | 2000 | 55 | 0.080 |
Why?
|
| Rats | 3 | 1996 | 130 | 0.080 |
Why?
|
| Cells | 1 | 2008 | 2 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 10 | 0.080 |
Why?
|
| Models, Biological | 1 | 2009 | 77 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 23 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 33 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 187 | 0.080 |
Why?
|
| Epithelial Cells | 3 | 2017 | 14 | 0.080 |
Why?
|
| Lipids | 1 | 2008 | 81 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2008 | 13 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 54 | 0.070 |
Why?
|
| Time Factors | 2 | 2002 | 507 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 40 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2007 | 1 | 0.070 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2007 | 2 | 0.070 |
Why?
|
| 3T3 Cells | 2 | 2017 | 2 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cadherins | 1 | 2006 | 2 | 0.060 |
Why?
|
| Escherichia coli | 2 | 1996 | 30 | 0.060 |
Why?
|
| Kinetics | 2 | 2002 | 65 | 0.060 |
Why?
|
| HIV | 1 | 2009 | 380 | 0.060 |
Why?
|
| Biomarkers | 1 | 2007 | 327 | 0.060 |
Why?
|
| Up-Regulation | 4 | 2007 | 23 | 0.060 |
Why?
|
| Amino Acid Sequence | 5 | 2004 | 139 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 1985 | 1 | 0.060 |
Why?
|
| Glutamates | 1 | 1985 | 1 | 0.060 |
Why?
|
| Purine Nucleosides | 1 | 1985 | 1 | 0.060 |
Why?
|
| Purine Nucleotides | 1 | 1985 | 1 | 0.060 |
Why?
|
| Synaptosomes | 1 | 1985 | 1 | 0.060 |
Why?
|
| Brain | 1 | 1985 | 53 | 0.060 |
Why?
|
| Ribosomal Proteins | 1 | 2004 | 3 | 0.060 |
Why?
|
| Genome | 1 | 2024 | 9 | 0.060 |
Why?
|
| Transcription Factor TFIIH | 1 | 2003 | 1 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 14 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2017 | 45 | 0.050 |
Why?
|
| Blotting, Southern | 2 | 1996 | 7 | 0.050 |
Why?
|
| Risk Factors | 1 | 2008 | 1475 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2003 | 1 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 4 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2002 | 4 | 0.050 |
Why?
|
| Podophyllotoxin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Viral Fusion Proteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 14 | 0.050 |
Why?
|
| DNA Adducts | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cell Extracts | 1 | 2002 | 3 | 0.050 |
Why?
|
| Cisplatin | 1 | 2002 | 5 | 0.050 |
Why?
|
| Fetus | 1 | 2002 | 8 | 0.050 |
Why?
|
| Mutagens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Animals, Outbred Strains | 1 | 2021 | 1 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2001 | 2 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2001 | 3 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2001 | 6 | 0.050 |
Why?
|
| Proteins | 1 | 2001 | 20 | 0.050 |
Why?
|
| Virus Integration | 1 | 2001 | 2 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2017 | 16 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 3 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 65 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 97 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2000 | 1 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2000 | 1 | 0.040 |
Why?
|
| Janus Kinase 3 | 1 | 2000 | 1 | 0.040 |
Why?
|
| Reference Values | 2 | 1991 | 64 | 0.040 |
Why?
|
| Hepatitis B e Antigens | 1 | 2000 | 26 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 1 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 442 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Peptide Initiation Factors | 1 | 1999 | 2 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 1999 | 2 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1999 | 5 | 0.040 |
Why?
|
| In Situ Hybridization | 3 | 2004 | 10 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2001 | 889 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 1997 | 8 | 0.040 |
Why?
|
| Rabbits | 1 | 1997 | 35 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 1997 | 20 | 0.040 |
Why?
|
| Immunization | 1 | 1997 | 63 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 4 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 7 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2017 | 1 | 0.030 |
Why?
|
| Luciferases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 1 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2017 | 1 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 20 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2017 | 36 | 0.030 |
Why?
|
| Diethylnitrosamine | 1 | 1996 | 1 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 2 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1995 | 1 | 0.030 |
Why?
|
| Retroviridae | 1 | 1995 | 1 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 7 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1995 | 7 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 1995 | 3 | 0.030 |
Why?
|
| Freezing | 1 | 1995 | 6 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1995 | 28 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 63 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 37 | 0.030 |
Why?
|
| RNA Stability | 1 | 2015 | 1 | 0.030 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2015 | 3 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2012 | 1 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 5 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 11 | 0.030 |
Why?
|
| Point Mutation | 1 | 1992 | 16 | 0.030 |
Why?
|
| Macrophages | 1 | 2012 | 15 | 0.030 |
Why?
|
| Deamination | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mosaic Viruses | 1 | 2012 | 1 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2012 | 4 | 0.020 |
Why?
|
| Plants, Genetically Modified | 1 | 2012 | 3 | 0.020 |
Why?
|
| Luciferases, Renilla | 1 | 2012 | 1 | 0.020 |
Why?
|
| Tobacco | 1 | 2012 | 14 | 0.020 |
Why?
|
| Drug Stability | 1 | 2011 | 13 | 0.020 |
Why?
|
| Biological Assay | 1 | 2012 | 32 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1991 | 1 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hepatitis, Chronic | 1 | 2009 | 1 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Ataxin-7 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 21 | 0.020 |
Why?
|
| Middle Aged | 2 | 2009 | 3601 | 0.020 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 1989 | 1 | 0.020 |
Why?
|
| Heterozygote | 1 | 2009 | 43 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 50 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 40 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 77 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 11 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 32 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 158 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 199 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 143 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 370 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 198 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2007 | 1 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2007 | 1 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2 | 0.020 |
Why?
|
| Agar | 1 | 2007 | 3 | 0.020 |
Why?
|
| Untranslated Regions | 1 | 2007 | 1 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2007 | 7 | 0.020 |
Why?
|
| Adult | 2 | 2009 | 5913 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2009 | 799 | 0.020 |
Why?
|
| Hepatoblastoma | 1 | 2006 | 1 | 0.020 |
Why?
|
| Male | 2 | 2009 | 6754 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2006 | 3 | 0.020 |
Why?
|
| Protein Transport | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cell Movement | 1 | 2006 | 13 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 22 | 0.020 |
Why?
|
| Biological Transport | 1 | 1985 | 11 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1985 | 2 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1985 | 28 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 1 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2004 | 1 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2004 | 4 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 1 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 2002 | 3 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 3 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 41 | 0.010 |
Why?
|
| Sequence Homology | 1 | 2001 | 11 | 0.010 |
Why?
|
| fas Receptor | 1 | 2001 | 13 | 0.010 |
Why?
|
| Aged | 1 | 2006 | 1740 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 27 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 2985 | 0.010 |
Why?
|